Elite Pharmaceuticals (OTCMKTS:ELTP) Issues Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, Zacks reports. Elite Pharmaceuticals had a negative return on equity of 0.72% and a net margin of 11.33%.

Elite Pharmaceuticals Stock Performance

Shares of ELTP opened at $0.44 on Wednesday. The firm has a market capitalization of $474.96 million, a PE ratio of 44.14 and a beta of 0.33. The company has a quick ratio of 6.34, a current ratio of 8.04 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.56. Elite Pharmaceuticals has a 52-week low of $0.27 and a 52-week high of $0.82.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.